| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Kristin Huse Haug, Inger Lise Bogen, Harald Osmundsen, Ivar Walaas, Frode Fonnu. Effects on cholinergic markers in rat brain and blood after short and prolonged administration of donepezil. Neurochemical research. vol 30. issue 12. 2006-03-21. PMID:16362770. |
donepezil is a selective inhibitor of acetylcholinesterase (ache) clinically used for treating alzheimer's disease. |
2006-03-21 |
2023-08-12 |
human |
| J M Rollinger, P Mocka, C Zidorn, E P Ellmerer, T Langer, H Stuppne. Application of the in combo screening approach for the discovery of non-alkaloid acetylcholinesterase inhibitors from Cichorium intybus. Current drug discovery technologies. vol 2. issue 3. 2006-03-10. PMID:16472227. |
because of the direct correlation of cholinergic deficit and the severity of dementia, alzheimer's disease is preferentially treated with acetylcholinesterase (ache) inhibitors to supplement the acetylcholine level. |
2006-03-10 |
2023-08-12 |
Not clear |
| Richard K Gordon, Julian R Haigh, Gregory E Garcia, Shawn R Feaster, Michael A Riel, David E Lenz, Paul S Aisen, Bhupendra P Docto. Oral administration of pyridostigmine bromide and huperzine A protects human whole blood cholinesterases from ex vivo exposure to soman. Chemico-biological interactions. vol 157-158. 2006-02-24. PMID:16256090. |
in the second fda human study for the treatment of alzheimer's disease, the wrair che wb assay was used to determine the rbc-ache and serum bche profile of healthy elderly volunteers receiving huperzine a. huperzine a is a plant-derived reversible and selective ache inhibitor compared to bche, and is a more potent inhibitor of ache than pb. |
2006-02-24 |
2023-08-12 |
human |
| Dov Barak, Arie Ordentlich, Dana Kaplan, Chanoch Kronman, Baruch Velan, Avigdor Shafferma. Lessons from functional analysis of AChE covalent and noncovalent inhibitors for design of AD therapeutic agents. Chemico-biological interactions. vol 157-158. 2006-02-24. PMID:16289124. |
thus, elucidation of the functional architecture of the huache active center is bound to be of considerable utility in the current effort to design novel covalent ache inhibitors as therapeutics for alzheimer's disease (ad). |
2006-02-24 |
2023-08-12 |
human |
| Georg Grön, Matthias Kirstein, Axel Thielscher, Matthias W Riepe, Manfred Spitze. Cholinergic enhancement of episodic memory in healthy young adults. Psychopharmacology. vol 182. issue 1. 2006-02-22. PMID:16021483. |
acetylcholine esterase (ache) inhibitors are known to remediate symptoms of alzheimer's disease. |
2006-02-22 |
2023-08-12 |
human |
| Ai-Ling Fu, Xing-Mei Zhang, Man-Ji Su. Antisense inhibition of acetylcholinesterase gene expression for treating cognition deficit in Alzheimer's disease model mice. Brain research. vol 1066. issue 1-2. 2006-02-15. PMID:16337925. |
to examine whether the selected antisense oligodeoxynucleotides (as-odn) targeting against human brain acetylcholinesterase (ache) mrna could improve the cognitive deficit in the alzheimer's disease (ad) model mice induced by amyloid-beta peptide (abeta), we determined the time-effect relationship of ache activity and the learning and memory after as-odn delivery. |
2006-02-15 |
2023-08-12 |
mouse |
| María-Ximena Silveyra, Natividad Cuadrado-Corrales, Alberto Marcos, María-Sagrario Barquero, Alberto Rábano, Miguel Calero, Javier Sáez-Valer. Altered glycosylation of acetylcholinesterase in Creutzfeldt-Jakob disease. Journal of neurochemistry. vol 96. issue 1. 2006-02-14. PMID:16277609. |
unlike alzheimer's disease, in which an alteration in both the glycosylation and levels of ache molecular forms is observed, the abnormal glycosylation of ache in cjd appears to be unrelated to changes in molecular forms of this enzyme. |
2006-02-14 |
2023-08-12 |
Not clear |
| L Bartorelli, C Giraldi, M Saccardo, S Cammarata, G Bottini, A M Fasanaro, A Trequattrin. Effects of switching from an AChE inhibitor to a dual AChE-BuChE inhibitor in patients with Alzheimer's disease. Current medical research and opinion. vol 21. issue 11. 2006-02-10. PMID:16307702. |
effects of switching from an ache inhibitor to a dual ache-buche inhibitor in patients with alzheimer's disease. |
2006-02-10 |
2023-08-12 |
Not clear |
| Tetsuya Shiraishi, Tatsuya Kikuchi, Kiyoshi Fukushi, Hitoshi Shinotoh, Shin-ichiro Nagatsuka, Noriko Tanaka, Tsuneyoshi Ota, Koichi Sato, Shigeki Hirano, Shuji Tanada, Masaomi Iyo, Toshiaki Iri. Estimation of plasma IC50 of donepezil hydrochloride for brain acetylcholinesterase inhibition in monkey using N-[11C]methylpiperidin-4-yl acetate ([11C]MP4A) and PET. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 30. issue 12. 2006-01-24. PMID:15920507. |
donepezil hydrochloride is a potent and selective inhibitor for brain acetylcholinesterase (ache) and is currently used worldwide for the treatment of alzheimer's disease. |
2006-01-24 |
2023-08-12 |
monkey |
| Esperanza Arias, Sonia Gallego-Sandín, Mercedes Villarroya, Antonio G García, Manuela G Lópe. Unequal neuroprotection afforded by the acetylcholinesterase inhibitors galantamine, donepezil, and rivastigmine in SH-SY5Y neuroblastoma cells: role of nicotinic receptors. The Journal of pharmacology and experimental therapeutics. vol 315. issue 3. 2006-01-23. PMID:16144975. |
donepezil, rivastigmine, and galantamine are three drugs with acetylcholinesterase (ache)-inhibiting activity that are currently being used to treat patients suffering from alzheimer's disease. |
2006-01-23 |
2023-08-12 |
human |
| Manami Kimura, Hiroko Komatsu, Hiroo Ogura, Kohei Sawad. Comparison of donepezil and memantine for protective effect against amyloid-beta(1-42) toxicity in rat septal neurons. Neuroscience letters. vol 391. issue 1-2. 2006-01-20. PMID:16154269. |
donepezil, a potent acetylcholinesterase (ache) inhibitor and memantine, an n-methyl-d-aspartate (nmda) receptor antagonist, have been used for the treatment of alzheimer's disease (ad), and both of them have been shown to have neuroprotective action against glutamate excitotoxicity. |
2006-01-20 |
2023-08-12 |
rat |
| Yehudit Hasin, Nili Avidan, Dani Bercovich, Amos D Korczyn, Israel Silman, Jacques S Beckmann, Joel L Sussma. Analysis of genetic polymorphisms in acetylcholinesterase as reflected in different populations. Current Alzheimer research. vol 2. issue 2. 2006-01-18. PMID:15974920. |
in addition, it was implicated in amyloid plaque formation, a hallmark of alzheimer's disease (ad), and most of the drugs used in ad treatment are ache inhibitors. |
2006-01-18 |
2023-08-12 |
human |
| Yoji Umezawa, Motohiro Nishi. CH/pi hydrogen bonds as evidenced in the substrate specificity of acetylcholine esterase. Biopolymers. vol 79. issue 5. 2006-01-04. PMID:16113998. |
the crystal structure of acetylcholine esterase (ache) in complex with various inhibitors, investigated as drugs for improvement of the cognitive ability of early stage alzheimer's disease, has been analyzed with the use of our program chpi. |
2006-01-04 |
2023-08-12 |
Not clear |
| Bozena Bukowsk. [Acetylcholinesterase--apoptosis induction, role in neurological diseases and leukemia]. Postepy biochemii. vol 51. issue 2. 2005-12-20. PMID:16209353. |
it was found that a peptide derived from ache may induce neuronal death and acetylcholinesterase may induce neurological changes in the development of alzheimer's disease. |
2005-12-20 |
2023-08-12 |
Not clear |
| Jan Mulder, Tibor Harkany, Katalin Czollner, Thomas I F H Cremers, Jan N Keijser, Csaba Nyakas, Paul G M Luite. Galantamine-induced behavioral recovery after sublethal excitotoxic lesions to the rat medial septum. Behavioural brain research. vol 163. issue 1. 2005-12-07. PMID:15951032. |
clinical trials show beneficial effects of acetylcholinesterase (ache) inhibitors, including galantamine, on cognitive functions in patients with mild to moderate alzheimer's disease. |
2005-12-07 |
2023-08-12 |
rat |
| Donna M Byers, Louis N Irwin, Donald E Moss, Isabel C Sumaya, Christine F Hohman. Prenatal exposure to the acetylcholinesterase inhibitor methanesulfonyl fluoride alters forebrain morphology and gene expression. Brain research. Developmental brain research. vol 158. issue 1-2. 2005-10-27. PMID:15964079. |
methanesulfonyl fluoride (msf) is a cns-selective acetylcholinesterase (ache) inhibitor, currently being developed and tested for the treatment of symptoms of alzheimer's disease. |
2005-10-27 |
2023-08-12 |
rat |
| Michael Happich, Bernd Schweikert, Axel Mühlbache. [Cost-effectiveness of galantamine in a german context]. Psychiatrische Praxis. vol 32. issue 3. 2005-09-29. PMID:15818530. |
we investigate the cost-effectiveness of the ache inhibitor galantamine for patients with alzheimer's disease (ad) in a german context. |
2005-09-29 |
2023-08-12 |
Not clear |
| Manami Kimura, Shigeru Akasofu, Hiroo Ogura, Kohei Sawad. Protective effect of donepezil against Abeta(1-40) neurotoxicity in rat septal neurons. Brain research. vol 1047. issue 1. 2005-08-24. PMID:15893738. |
donepezil, a potent acetylcholinesterase (ache) inhibitor used for the treatment of alzheimer's disease (ad), is thought to have a neuroprotective effect in ad patients. |
2005-08-24 |
2023-08-12 |
rat |
| Kaj Blenno. Cerebrospinal fluid protein biomarkers for Alzheimer's disease. NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics. vol 1. issue 2. 2005-08-23. PMID:15717022. |
the introduction of acetylcholine esterase (ache) inhibitors as a symptomatic treatment of alzheimer's disease (ad) has made patients seek medical advice at an earlier stage of the disease. |
2005-08-23 |
2023-08-12 |
Not clear |
| Federica Belluti, Angela Rampa, Lorna Piazzi, Alessandra Bisi, Silvia Gobbi, Manuela Bartolini, Vincenza Andrisano, Andrea Cavalli, Maurizio Recanatini, Piero Valent. Cholinesterase inhibitors: xanthostigmine derivatives blocking the acetylcholinesterase-induced beta-amyloid aggregation. Journal of medicinal chemistry. vol 48. issue 13. 2005-08-23. PMID:15974596. |
all of the compounds had ache ic(50) values in the nanomolar range and showed the ability to block the ache-induced abeta aggregation, thus supporting the feasibility of this new strategy in the search of compounds for the treatment of alzheimer's disease. |
2005-08-23 |
2023-08-12 |
Not clear |